Alteplase fibrinolysis

Description Results NMA

Initial TIMI 3 flow 5.20 [2.63; 10.29]

Short-term death 1.22 [0.39; 3.81]

Short-term major bleeding in patients treated NaN [NaN; NaN]

Short-term non-fatal reinfarction 4.05 [0.46; 35.42]

Short-term urgent target vessel revascularisation 6.08 [0.75; 49.29]

Final TIMI 3 flow 0.89 [0.78; 1.02]

Initial TIMI 3 flow 2.19 [1.60; 2.99]

Short-term death 1.11 [0.48; 2.57]

Short-term major bleeding in patients treated 1.05 [0.62; 1.77]

Short-term non-fatal reinfarction 1.13 [0.44; 2.90]

Final TIMI 3 flow 0.98 [0.92; 1.04]

facilated PCI with Alteplase 50 mg(intravenous bolus)mag (n=74)

vs.

primary intervention (n=75)

Sample size: 74/75

Primary endpoint:

FU duration: 42-day

facilated PCI with alteplase 50 mg (intravenous bolus) (n=302)

vs.

primary intervention (n=304)

Sample size: 302/304

Primary endpoint:

FU duration: 30-day